Autopsy report · NCT03347617
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
Cause of deathStaffing, sites or logistics
“Principal investigator transition”
Life of this trial
- Registered 2 months before it started.
- Ran for about 7 years 6 months before it stopped.
- 52 participants enrolled.
- Results were posted on the registry 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- OHSU Knight Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Glioblastoma
- Interventions
- Ferumoxytol; Laboratory Biomarker Analysis; Magnetic Resonance Imaging; Pembrolizumab
- Participants
- 52
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Psychometric Validation of the "Antillanisée" Version of the Mini Mental State Examination (MMSEa)
“Departure of the Principal Investigator” - "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot Study to Assess the Value of Written Information Documents.
“Principal Investigator's departure” - Changes in Muscle Activation When Carrying Backpacks
“Change of a principal investigator” - Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion
“Departure of the principal investigator and lack of succession” - Interest of Virtual Reality for the Management of Hospitalized Pregnant Patients at Risk of Preterm Delivery
“departure of the principal investigator without replacement”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.